Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease
Publication
, Journal Article
Newby, K; Cliff, R; White, H; Kong, DF
Published in: Evidence-based Cardiovascular Medicine
January 1, 2003
Duke Scholars
Published In
Evidence-based Cardiovascular Medicine
DOI
ISSN
1361-2611
Publication Date
January 1, 2003
Volume
7
Issue
1
Start / End Page
8 / 9
Related Subject Headings
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Newby, K., Cliff, R., White, H., & Kong, D. F. (2003). Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease. Evidence-Based Cardiovascular Medicine, 7(1), 8–9. https://doi.org/10.1016/S1361-2611(02)00139-2
Newby, K., R. Cliff, H. White, and D. F. Kong. “Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease.” Evidence-Based Cardiovascular Medicine 7, no. 1 (January 1, 2003): 8–9. https://doi.org/10.1016/S1361-2611(02)00139-2.
Newby K, Cliff R, White H, Kong DF. Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease. Evidence-based Cardiovascular Medicine. 2003 Jan 1;7(1):8–9.
Newby, K., et al. “Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease.” Evidence-Based Cardiovascular Medicine, vol. 7, no. 1, Jan. 2003, pp. 8–9. Scopus, doi:10.1016/S1361-2611(02)00139-2.
Newby K, Cliff R, White H, Kong DF. Oral glycoprotein IIb/IIIa inhibitors are associated with increased mortality and myocardial infarction in coronary artery disease. Evidence-based Cardiovascular Medicine. 2003 Jan 1;7(1):8–9.
Published In
Evidence-based Cardiovascular Medicine
DOI
ISSN
1361-2611
Publication Date
January 1, 2003
Volume
7
Issue
1
Start / End Page
8 / 9
Related Subject Headings
- Cardiovascular System & Hematology